CalciMedica Set to Showcase Innovative Research at Medical Conferences

CalciMedica Set to Showcase Innovative Research at Major Medical Conferences

CalciMedica Inc., a clinical-stage biopharmaceutical company, is poised to present its groundbreaking research at the upcoming Digestive Disease Week (DDW) 2025 and the American Society of Nephrology (ASN) Conference. These events are significant platforms where the latest research findings in medicine are shared, and CalciMedica is eager to contribute.

Key Presentations Overview

During DDW 2025, taking place from May 3 to 6 in San Diego, California, CalciMedica will showcase a poster presentation entitled "Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS) Have a Larger Volume of Distribution Compared to Healthy Volunteers." This poster will be presented by Dr. Kenneth A. Stauderman, co-Founder and Chief Scientific Officer of CalciMedica, on Saturday, May 3, from 12:30 PM to 1:30 PM PT. This study could shed light on how the physiological responses of patients with acute conditions differ from those of healthy individuals, providing valuable insights into treatment approaches.

In addition to DDW, CalciMedica will also participate in the ASN’s 3rd Acute Kidney Injury From Bench to Bedside Conference in Leesburg, Virginia, scheduled for May 4 to 7. The company's Chief Medical Officer, Dr. Sudarshan Hebbar, will take center stage with an oral presentation discussing "Experiences with AKI Clinical Trial Design." This presentation will occur on Tuesday, May 6, between 8:00 AM and 10:00 AM ET, and will focus on the challenges and experiences faced while designing clinical trials for Acute Kidney Injury (AKI) patients.

Moreover, Dr. Hebbar will join a panel discussion titled "Session 3 Roundtable Discussions - Non-Academic Careers in Science" on Wednesday, May 7, at 4:00 PM to 4:30 PM. This discussion is expected to generate critical thoughts about career paths within the scientific community beyond traditional academic roles.

About CalciMedica

CalciMedica is at the forefront of biopharmaceutical innovations, particularly in developing new therapies targeting calcium release-activated calcium (CRAC) channels. These channels play a pivotal role in a range of inflammatory and immunologic diseases. By inhibiting CRAC channels, CalciMedica aims to modulate immune responses and safeguard against tissue damage, addressing unmet medical needs in conditions that currently have no approved treatments.

One of the company’s standout product candidates, Auxora™, has already demonstrated promising results across multiple clinical trials. Notably, recent findings from the Phase 2b CARPO trial (NCT04681066) indicate its potential in treating acute pancreatitis. Additionally, CalciMedica is pursuing further research with ongoing trials for conditions such as COVID pneumonia, acute kidney injury, and even pediatric care regarding asparaginase-induced pancreatic toxicity.

Conclusion

With its focus on leveraging innovative scientific research to drive therapeutic advancements, CalciMedica is set to make waves at these upcoming conferences. The data presented could not only advance clinical understanding but also catalyze new discussions around effective treatments and the future of biopharmaceutical research. Updates and further details about the presentations will soon be available on CalciMedica's investor relations website, ensuring that those interested can stay informed about these vital medical discussions.

For more information about CalciMedica and its ongoing developments in biopharmaceuticals, visit www.calcimedica.com.